Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus and its licensee Genevant filed three international lawsuits against Pfizer and BioNTech to enforce LNP patents, targeting their COVID-19 vaccines in Canada and Europe. The company received approximately $178 million from Moderna as its share of a noncontingent settlement payment resolving prior patent litigation.
Key figures
- Genevant equity ownership
- 16%
- Planned capital return usd
- $230M
- Moderna settlement payment usd
- $178M
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.